fenoterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	1155	13392-18-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fenoterol phenoterol fenoterol hydrobromide fenoterol hydrochloride fenoterol HCl	A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. Molecular weight: 303.36 Formula: C17H21NO4 CLOGP: 0.98 LIPINSKI: 0 HAC: 5 HDO: 5 TPSA: 92.95 ALOGS: -3.27 ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fenoterol
phenoterol
fenoterol hydrobromide
fenoterol hydrochloride
fenoterol HCl

A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.

Molecular weight: 303.36
Formula: C17H21NO4
CLOGP: 0.98
LIPINSKI: 0
HAC: 5
HDO: 5
TPSA: 92.95
ALOGS: -3.27
ROTB: 6

Drug dosage:

Dose	Unit	Route
0.60	mg	Inhal.aerosol
0.60	mg	Inhal.powder
4	mg	Inhal.solution
10	mg	O
10	mg	R

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.08 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	2 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	29 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.53 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.87 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.16 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1965	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Congenital coronary artery malformation	68.43	28.62	10	1680	138	63487194
Polyneuropathy	51.53	28.62	18	1672	14571	63472761
Pancreatic steatosis	49.19	28.62	10	1680	1006	63486326
Acute respiratory failure	48.94	28.62	22	1668	34463	63452869
Asthmatic crisis	48.80	28.62	11	1679	1802	63485530
Polyhydramnios	46.34	28.62	11	1679	2260	63485072
Arterial thrombosis	45.69	28.62	10	1680	1433	63485899
Sinus arrhythmia	45.48	28.62	10	1680	1463	63485869
Cervical incompetence	41.54	28.62	8	1682	609	63486723
Erysipelas	36.77	28.62	12	1678	7893	63479439
Delirium	32.75	28.62	19	1671	50522	63436810
Hypercapnia	32.54	28.62	10	1680	5421	63481911
Asthma	30.47	28.62	26	1664	127535	63359797
Renal cyst	29.92	28.62	11	1679	10291	63477041
Systemic infection	29.71	28.62	9	1681	4651	63482681

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood phosphorus increased	90.02	28.23	31	2873	7690	34946337
Appendicolith	82.98	28.23	30	2874	8571	34945456
Appendicitis	67.20	28.23	30	2874	14777	34939250
Myasthenia gravis	62.45	28.23	23	2881	6917	34947110
Cardiogenic shock	61.30	28.23	34	2870	26584	34927443
Ventricular fibrillation	57.50	28.23	31	2873	22923	34931104
Stress	54.55	28.23	33	2871	30314	34923713
Dry mouth	49.62	28.23	31	2873	30134	34923893
Chronic obstructive pulmonary disease	48.98	28.23	37	2867	48881	34905146
Blood uric acid increased	48.50	28.23	21	2883	9603	34944424
Abdominal distension	43.15	28.23	37	2867	58455	34895572
Congenital cystic lung	40.19	28.23	8	2896	226	34953801
Bacterial infection	37.09	28.23	21	2883	17042	34936985
General physical health deterioration	36.67	28.23	49	2855	128220	34825807
Ascites	35.43	28.23	30	2874	46541	34907486
Xanthelasma	33.45	28.23	6	2898	95	34953932
Neonatal respiratory failure	31.07	28.23	7	2897	361	34953666
Blood cholesterol increased	30.99	28.23	20	2884	20523	34933504
Hyperphosphataemia	30.19	28.23	12	2892	4425	34949602
Hydrops foetalis	29.76	28.23	8	2896	859	34953168
Tobacco abuse	29.74	28.23	7	2897	439	34953588
Condition aggravated	29.26	28.23	55	2849	192141	34761886

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	95.87	23.91	30	4264	8521	79731573
Blood phosphorus increased	94.25	23.91	31	4263	10316	79729778
Appendicitis	69.86	23.91	30	4264	20764	79719330
Chronic obstructive pulmonary disease	64.72	23.91	46	4248	85373	79654721
Congenital coronary artery malformation	63.80	23.91	10	4284	106	79739988
Ventricular fibrillation	63.39	23.91	32	4262	31894	79708200
Myasthenia gravis	63.07	23.91	23	4271	10376	79729718
Cardiogenic shock	60.59	23.91	34	4260	41880	79698214
General physical health deterioration	55.42	23.91	71	4223	275167	79464927
Acute respiratory failure	49.60	23.91	34	4260	59507	79680587
Blood uric acid increased	47.26	23.91	20	4274	13340	79726754
Pancreatic steatosis	40.96	23.91	10	4284	1135	79738959
Stress	40.80	23.91	34	4260	79578	79660516
Ascites	40.24	23.91	33	4261	75529	79664565
Asthmatic crisis	39.98	23.91	11	4283	1995	79738099
Abdominal distension	39.61	23.91	40	4254	119610	79620484
Polyhydramnios	36.92	23.91	10	4284	1710	79738384
Sinus arrhythmia	34.90	23.91	10	4284	2100	79737994
Dry mouth	33.94	23.91	32	4262	87987	79652107
Asthma	33.88	23.91	39	4255	135056	79605038
Dyspnoea	33.07	23.91	111	4183	856914	78883180
Xanthelasma	32.89	23.91	6	4288	165	79739929
Arterial thrombosis	32.56	23.91	10	4284	2664	79737430
Cervical incompetence	31.59	23.91	7	4287	520	79739574
Hyperphosphataemia	31.01	23.91	12	4282	6364	79733730
Electrocardiogram abnormal	30.95	23.91	16	4278	16721	79723373
Polyneuropathy	30.63	23.91	18	4276	24133	79715961
Systemic infection	29.26	23.91	13	4281	9739	79730355
Somnolence	28.20	23.91	48	4246	238933	79501161
Infective exacerbation of chronic obstructive airways disease	28.01	23.91	9	4285	2775	79737319
Erysipelas	27.93	23.91	13	4281	10837	79729257
Tobacco abuse	27.09	23.91	7	4287	999	79739095
Analgesic therapy	27.07	23.91	7	4287	1002	79739092
Sleep disorder therapy	26.97	23.91	7	4287	1017	79739077
Bacterial infection	26.36	23.91	18	4276	31262	79708832
Drug therapy	25.86	23.91	7	4287	1194	79738900
Multiple organ dysfunction syndrome	25.68	23.91	32	4262	120214	79619880
Hyponatraemia	25.44	23.91	39	4255	177809	79562285
Traumatic haemorrhage	25.14	23.91	7	4287	1326	79738768
Iron deficiency	25.08	23.91	12	4282	10642	79729452
Condition aggravated	23.93	23.91	70	4224	501054	79239040

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G02CA03	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Sympathomimetics, labour repressants
ATC	R03AC04	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists
ATC	R03AL01	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03CC04	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058666	Adrenergic beta-2 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D012102	Reproductive Control Agents
MeSH PA	D019141	Respiratory System Agents
MeSH PA	D013566	Sympathomimetics
MeSH PA	D015149	Tocolytic Agents
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35523	bronchodilator
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:66993	tocolytic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.48	acidic
pKa2	11.02	acidic
pKa3	11.67	acidic
pKa4	12.2	acidic
pKa5	8.03	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	EC50	6.90		WOMBAT-PK	IUPHAR
Beta-2 adrenergic receptor	GPCR		ADRB2_CAVPO		IC50	7.22		CHEMBL

External reference:

ID	Source
4025246	VUID
N0000171778	NUI
D01428	KEGG_DRUG
4025246	VANDF
C0015840	UMLSCUI
CHEBI:149226	CHEBI
CHEMBL32800	ChEMBL_ID
DB01288	DRUGBANK_ID
D005280	MESH_DESCRIPTOR_UI
3343	PUBCHEM_CID
557	IUPHAR_LIGAND_ID
3073	INN_ID
36369-23-0	SECONDARY_CAS_RN
1944-10-1	SECONDARY_CAS_RN
22M9P70OQ9	UNII
203124	RXNORM
003460	NDDF
003461	NDDF
349924004	SNOMEDCT_US
395976006	SNOMEDCT_US
396053003	SNOMEDCT_US
CHEMBL537445	ChEMBL_ID
130156-24-0	SECONDARY_CAS_RN

Pharmaceutical products:

None